IR-MED Names Moshe Gerber as New CEO

ROSH PINNA, Israel, May 10, 2022–(BUSINESS WIRE)–IR-Med (“IR-MED or the “Company“) (OTCQB:IRME), an innovative development-stage medical device company utilizing Infra-Red light spectroscopy (IR) and Artificial Intelligence (AI) technologies to develop non-invasive detection devices, today announced the appointment of Moshe Gerber as Chief Executive Officer, effective immediately. Mr. Gerber brings more than 25 years’ experience in international […]

IR-Med Announces $3.2 Million Private Placement

ROSH PINNA, Israel, April 14, 2022–(BUSINESS WIRE)–IR-Med (“IR-MED or the “Company“) (OTCQB:IRME), an innovative development stage medical device company that utilizes Infra-Red light spectroscopy (IR) combined with Artificial Intelligence (AI) technologies, announced that it has entered into a Subscription Agreements with certain investors for the sale of 3,636,364 shares at a per share price of $0.88 […]

Following Its Recent Annual Updates: IR-Med Announces OTCQB Up-listing: “A Significant Achievement for the Company”

ROSH PINNA, Israel, January 25, 2022–(BUSINESS WIRE)–IR-Med (“IR-Med or the “Company“) (OTC:IRME) is pleased to announce that IR-Med has been approved by OTC Markets to up-list from Pink Sheet to the OTCQB tier after IR-Med satisfied the required uplist criteria. Effective as of February 1st, 2022, IR-Med will trade on the OTCQB exchange under its current symbol […]

IR-Med Letter to Shareholders

New York, N.Y., Jan. 11, 2022 (GLOBE NEWSWIRE) — IR-Med, Inc. (OTCPINK: IRME). Our non-invasive monitoring technology enters the public eye – why I’m so excited for 2022. Dear new, old, and prospective IR-Med shareholders, Welcome to IR-MED. After months of behind-the-scenes efforts, I’m excited to share with you what we’re working–and why I’m looking forward […]